Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials

[FDA]

This guidance is intended for sponsors of cancer immunotherapeutic drugs that modulate the endogenous immune system and may break immunologic tolerance to normal organs and tissues and provides recommendations regarding the data that should be collected and evaluated to assess these adverse events.


Baca selengkapnya di : http://www.fda.gov...